Cytoskeleton-associated protein 2 is a potential predictive marker for risk of early and extensive recurrence of hepatocellular carcinoma after operative resection

Surgery (United States)

Volumn 155, Issue 1, 2014, Pages 114-123

  Hayashi, Tatsuya ^a   Ohtsuka, Masayuki ^a   Okamura, Daiki ^a   Seki, Naohiko ^a   Kimura, Fumio ^a   Shimizu, Hiroaki ^a   Yoshidome, Hiroyuki ^a   Kato, Atsushi ^a   Yoshitomi, Hideyuki ^a   Furukawa, Katsunori ^a   Miyazaki, Masaru ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSKELETON ASSOCIATED PROTEIN 2; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; UNCLASSIFIED DRUG; CKAP2 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; DISEASE COURSE; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GENE; JAPAN; LIVER; LIVER TUMOR; METABOLISM; MORTALITY; PATHOLOGY; TUMOR RECURRENCE;

AGED; CARCINOMA, HEPATOCELLULAR; CYTOSKELETAL PROTEINS; FEMALE; HUMANS; JAPAN; LIVER; LIVER NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84899474073     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2013.06.009     Document Type: Article

References (26)

1. Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 2008; 112: 250-9.
2. Livraghi T, Mäkisalo H, Line PD. Treatment options in hepatocellular carcinoma today. Scand J Surg 2011; 100: 22-9.
3. Levi DM, Nishida S. Liver transplantation for hepatocellular carcinoma: lessons learned and future directions. Clin Liver Dis 2011; 15: 717-25.
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
5. Koniaris LG, Levi DM, Pedroso FE, Franceschi D, Tzakis AG, Santamaria-Barria JA, et al. Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma? Ann Surg 2011; 254: 527-38.
6. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002; 235: 373-82.
7. Hayashi M, Shimizu T, Hirokawa F, Inoue Y, Komeda K, Asakuma M, et al. Clinicopathological risk factors for recurrence within one year after initial hepatectomy for hepatocellular carcinoma. Am Surg 2011; 77: 572-8.
8. Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 2007; 141: 330-9.
9. Belghiti J, Cortes A, Abdalla EK, Régimbeau JM, Prakash K, Durand F, et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003; 238: 885-92.
10. Sala M, Fuster J, Llovet JM, Navasa M, Solé M, Varela M, et al. Barcelona Clinic Liver Cancer (BCLC) Group. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl 2004; 10: 1294-300.
11. Scatton O, Zalinski S, Terris B, Lefevre JH, Casali A, Massault PP, et al. Hepatocellular carcinoma developed on compensated cirrhosis: resection as a selection tool for liver transplantation. Liver Transpl 2008; 14: 779-88.
12. Shimozawa N, Hanazaki K. Long-term prognosis after hepatic resection for small hepatocellular carcinoma. J Am Coll Surg 2004; 198: 356-65.
13. Goldsmith PJ, Toogood GJ, Lodge JPA, Prasad KR. Salvage transplantation for stage IVa hepatocellular carcinoma, what are the guidelines? Clin Transplant 2009; 23: 581.
14. Bae CD, Sung YS, Jeon SM, Suh Y, Yang HK, Kim YI, et al. Up-regulation of cytoskeletal-associated protein 2 in primary human gastric adenocarcinomas. J Cancer Res Clin Oncol 2003; 129: 621-30.
15. Maouche-Chrétien L, Deleu N, Badoual C, Fraissignes P, Berger R, Gaulard P, et al. Identification of a novel cDNA, encoding a cytoskeletal associated protein, differentially expressed in diffuse large B cell lymphomas. Oncogene 1998; 17: 1245-51.
16. Eichmuller S, Usener D, Dummer R, Stein A, Thiel D, Schadendorf D. Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Nat Acad Sci USA 2001; 98: 629-34.
17. Jin Y, Murakumo Y, Ueno K, Hashimoto M, Watanabe T, Shimoyama Y, et al. Identification of a mouse cytoskeletonassociated protein, CKAP2, with microtubule-stabilizing properties. Cancer Sci 2004; 95: 815-21.
18. Tsuchihara K, Lapin V, Bakal C, Okada H, Brown L, Hirota- Tsuchihara M, et al. Ckap2 regulates aneuploidy, cell cycling, and cell death in a p53-dependent manner. Cancer Res 2005; 65: 6685-91.
19. Hong KU, Park YS, Seong YS, Kang D, Bae CD, Park J. Functional importance of the anaphase-promoting complex- Cdh1-mediated degradation of TMAP/CKAP2 in regulation of spindle function and cytokinesis. Mol Cell Biol 2007; 27: 3667-81.
20. Hong KU, Kim E, Bae CD, Park J. TMAP/CKAP2 is essential for proper chromosome segregation. Cell Cycle 2009; 8: 314-24.
21. Sobin LH, Gospodarowicz MK, Wittekind CH, editors. International union against cancer: TNM classification of malignant tumours. 7th ed. Chichester (West Sussex, UK): Wiley-Blackwell; 2010.
22. Hsia CC, Nakashima Y, Thorgeirsson SS, Harris CC, Minemura M, Momosaki S, et al. Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma. Oncol Rep 2000; 7: 353-6.
23. Chen GG, Merchant JL, Lai PB, Ho RL, Hu X, Okada M, et al. Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89. Am J Pathol 2003; 162: 1823-9.
24. Tanaka S, Arii S, Yasen M, Mogushi K, Su NT, Zhao C, et al. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg 2008; 95: 611-9.
25. Kim HJ, Kwon HR, Bae CD, Park J, Hong KU. Specific primary sequence requirements for Aurora B kinase-mediated phosphorylation and subcellular localization of TMAP during mitosis. Cell Cycle 2010; 9: 2027-36.
26. Ban G, Jeong JS, Kim A, Kim SJ, Han SY, Kim IH, et al. Selective and efficient retardation of cancers expressing cytoskeleton-associated protein 2 by targeted RNA replacement. Int J Cancer 2011; 129: 1018-29.